TREATMENT OF LIPID TRANSPORT AND METABOLISM GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A LIPID TRANSPORT AND METABOLISM GENE
First Claim
Patent Images
1. A method of modulating a function of and/or the expression of a Lipid transport and metabolism gene polynucleotide in patient cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within nucleotides 1 to 1299 of SEQ ID NO;
8, 1 to 918 of SEQ ID NO;
9, 1 to 1550 of SEQ ID NO;
10, 1 to 329 of SEQ ID NO;
11, 1 to 1826 of SEQ ID NO;
12, 1 to 536 of SEQ ID NO;
13, 1 to 551 of SEQ ID NO;
14, 1 to 672 of SEQ ID NO;
15, 1 to 616 of SEQ ID NO;
16, 1 to 471 of SEQ ID NO;
17, 1 to 707 of SEQ ID NO;
18, 1 to 741 of SEQ ID NO;
19, 1 to 346 of SEQ ID NO;
20, 1 to 867 of SEQ ID NO;
21, 1 to 563 of SEQ ID NO;
22 (FIG. 3);
thereby modulating a function of and/or the expression of the Lipid transport and metabolism gene polynucleotide in patient cells or tissues in vivo or in vitro.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Lipid transport and metabolism gene, in particular, by targeting natural antisense polynucleotides of a Lipid transport and metabolism gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of a Lipid transport and metabolism genes.
21 Citations
37 Claims
-
1. A method of modulating a function of and/or the expression of a Lipid transport and metabolism gene polynucleotide in patient cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within nucleotides 1 to 1299 of SEQ ID NO;
8, 1 to 918 of SEQ ID NO;
9, 1 to 1550 of SEQ ID NO;
10, 1 to 329 of SEQ ID NO;
11, 1 to 1826 of SEQ ID NO;
12, 1 to 536 of SEQ ID NO;
13, 1 to 551 of SEQ ID NO;
14, 1 to 672 of SEQ ID NO;
15, 1 to 616 of SEQ ID NO;
16, 1 to 471 of SEQ ID NO;
17, 1 to 707 of SEQ ID NO;
18, 1 to 741 of SEQ ID NO;
19, 1 to 346 of SEQ ID NO;
20, 1 to 867 of SEQ ID NO;
21, 1 to 563 of SEQ ID NO;
22 (FIG. 3 );
thereby modulating a function of and/or the expression of the Lipid transport and metabolism gene polynucleotide in patient cells or tissues in vivo or in vitro. - View Dependent Claims (13)
- contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within nucleotides 1 to 1299 of SEQ ID NO;
-
2. A method of modulating a function of and/or the expression of a Lipid transport and metabolism gene polynucleotide in patient cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of a Lipid transport and metabolism gene polynucleotide;
thereby modulating a function of and/or the expression of the Lipid transport and metabolism gene polynucleotide in patient cells or tissues in vivo or in vitro.
- contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of a Lipid transport and metabolism gene polynucleotide;
-
3. A method of modulating a function of and/or the expression of a Lipid transport and metabolism gene polynucleotide in patient cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to an antisense oligonucleotide to the Lipid transport and metabolism gene polynucleotide;
thereby modulating a function of and/or the expression of the Lipid transport and metabolism gene polynucleotide in patient cells or tissues in vivo or in vitro.
- contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to an antisense oligonucleotide to the Lipid transport and metabolism gene polynucleotide;
-
4. A method of modulating a function of and/or the expression of a Lipid transport and metabolism gene polynucleotide in patient cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one antisense oligonucleotide that targets a region of a natural antisense oligonucleotide of the Lipid transport and metabolism gene polynucleotide;
thereby modulating a function of and/or the expression of the Lipid transport and metabolism gene polynucleotide in patient cells or tissues in vivo or in vitro. - View Dependent Claims (5, 6, 7, 8, 9, 10, 11, 12)
- contacting said cells or tissues with at least one antisense oligonucleotide that targets a region of a natural antisense oligonucleotide of the Lipid transport and metabolism gene polynucleotide;
-
14. A method of modulating a function of and/or the expression of a Lipid transport and metabolism gene in mammalian cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide 5 to 30 nucleotides in length, said at least one siRNA oligonucleotide being specific for an antisense polynucleotide of a Lipid transport and metabolism gene polynucleotide, wherein said at least one siRNA oligonucleotide has at least 50% sequence identity to a complementary sequence of at least about five consecutive nucleic acids of the antisense and/or sense nucleic acid molecule of the Lipid transport and metabolism gene polynucleotide; and
, modulating a function of and/or the expression of a Lipid transport and metabolism gene in mammalian cells or tissues in vivo or in vitro. - View Dependent Claims (15)
- contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide 5 to 30 nucleotides in length, said at least one siRNA oligonucleotide being specific for an antisense polynucleotide of a Lipid transport and metabolism gene polynucleotide, wherein said at least one siRNA oligonucleotide has at least 50% sequence identity to a complementary sequence of at least about five consecutive nucleic acids of the antisense and/or sense nucleic acid molecule of the Lipid transport and metabolism gene polynucleotide; and
-
16. A method of modulating a function of and/or the expression of a Lipid transport and metabolism gene in mammalian cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one antisense oligonucleotide of about 5 to 30 nucleotides in length specific for noncoding and/or coding sequences of a sense and/or natural antisense strand of a Lipid transport and metabolism gene polynucleotide wherein said at least one antisense oligonucleotide has at least 50% sequence identity to at least one nucleic acid sequence set forth as SEQ ID NOS;
1 to 7 and 8 to 22; and
, modulating the function and/or expression of the Lipid transport and metabolism gene in mammalian cells or tissues in vivo or in vitro.
- contacting said cells or tissues with at least one antisense oligonucleotide of about 5 to 30 nucleotides in length specific for noncoding and/or coding sequences of a sense and/or natural antisense strand of a Lipid transport and metabolism gene polynucleotide wherein said at least one antisense oligonucleotide has at least 50% sequence identity to at least one nucleic acid sequence set forth as SEQ ID NOS;
-
17. A synthetic, modified oligonucleotide comprising at least one modification wherein the at least one modification is selected from:
- at least one modified sugar moiety;
at least one modified internucleotide linkage;
at least one modified nucleotide, and combinations thereof;
wherein said oligonucleotide is an antisense compound which hybridizes to and modulates the function and/or expression of a Lipid transport and metabolism gene in vivo or in vitro as compared to a normal control. - View Dependent Claims (18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)
- at least one modified sugar moiety;
- 30. A composition comprising one or more oligonucleotides specific for one or more Lipid transport and metabolism gene polynucleotides, said polynucleotides comprising antisense sequences, complementary sequences, alleles, homologs, isoforms, variants, derivatives, mutants, fragments, or combinations thereof.
-
35. A method of preventing or treating a disease associated with at least one Lipid transport and metabolism gene polynucleotide and/or at least one encoded product thereof, comprising:
- administering to a patient a therapeutically effective dose of at least one antisense oligonucleotide that binds to a natural antisense sequence of said at least one Lipid transport and metabolism gene polynucleotide and modulates expression of said at least one Lipid transport and metabolism gene polynucleotide;
thereby preventing or treating the disease associated with the at least one Lipid transport and metabolism gene polynucleotide and/or at least one encoded product thereof. - View Dependent Claims (36)
- administering to a patient a therapeutically effective dose of at least one antisense oligonucleotide that binds to a natural antisense sequence of said at least one Lipid transport and metabolism gene polynucleotide and modulates expression of said at least one Lipid transport and metabolism gene polynucleotide;
-
37. A method of identifying and selecting at least one oligonucleotide for in vivo administration comprising:
- selecting a target polynucleotide associated with a disease state;
identifying at least one oligonucleotide comprising at least five consecutive nucleotides which are complementary to the selected target polynucleotide or to a polynucleotide that is antisense to the selected target polynucleotide;
measuring the thermal melting point of a hybrid of an antisense oligonucleotide and the target polynucleotide or the polynucleotide that is antisense to the selected target polynucleotide under stringent hybridization conditions; and
selecting at least one oligonucleotide for in vivo administration based on the information obtained.
- selecting a target polynucleotide associated with a disease state;
Specification